Evidence summary: which treatment and which cancer question?
| Option | What the evidence shows | Evidence grade | Key safety notes |
|---|---|---|---|
| WHI oral conjugated equine estrogens + medroxyprogesterone acetate — breast cancer findings in women with a uterus | More breast cancer cases than placebo in long-term follow-up. The difference in breast cancer deaths was not statistically significant. Follow-up included years after trial treatment ended. WHI — original combined oral hormone trial (2002) WHI — long-term breast cancer incidence and mortality follow-up (2020) | No separate book grade | This is a finding for the named regimen and study group. Do not assign its exact risk unchanged to every other hormone, progestogen or route. |
| WHI oral conjugated equine estrogens alone — breast cancer findings in women with a prior hysterectomy | Fewer breast cancer cases and deaths than that trial's placebo group in long-term follow-up. This was a separate trial, not a randomised comparison of adding versus omitting a progestogen in one common group. WHI — long-term breast cancer incidence and mortality follow-up (2020) The Menopause Society — 2022 Hormone Therapy Position Statement | No separate book grade | The finding does not justify systemic estrogen without appropriate uterine protection in someone who has a uterus, or establish the same outcome for every estrogen preparation. |
| Systemic hormone therapy after breast cancer — the HABITS proposition | Extended follow-up found more new breast-cancer events among those assigned hormone therapy, mainly systemic estradiol with a progestogen. The book appraises routine use in this context unfavourably. HABITS — new breast-cancer events after systemic hormone therapy | E | Not a routine choice after breast cancer. Exceptional decisions need specialist assessment of the actual cancer, symptoms and alternatives. Compounded or ‘bioidentical’ labels do not establish a safe substitute. |
| Low-dose vaginal estrogen after breast cancer — cancer-safety claim | Observational reassurance has important limits. A Danish cohort found no overall recurrence increase among vaginal-estrogen users, but an increased recurrence signal in the aromatase-inhibitor subgroup. Danish observational cohort — systemic or vaginal hormones after early breast cancer ACOG — urogenital symptom care after estrogen-dependent breast cancer | C | This is a cancer-safety grade, not a symptom-efficacy grade. Local exposure is lower than systemic HRT but not zero. The product and cancer treatment need review; aromatase-inhibitor users need particular cancer-team input. |
| MENOS 1 group CBT after breast cancer — hot-flash and night-sweat problem ratings | The structured program reduced how problematic symptoms felt, with benefit maintained at follow-up. This is evidence for symptom burden, not for eliminating every episode or changing cancer risk. MENOS 1 — group CBT for menopausal symptom burden after breast cancer | B | Use appropriate trained support. CBT should not replace assessment of new symptoms or become a condition for other care. Trauma or severe mental-health concerns need suitable support. |
Important grading note: The first two rows report WHI breast-cancer findings for which this guide does not invent an A–E letter: the book's WHI E grades concern different prevention outcomes. The E, C and B above reproduce chapter 42's specific treatment claims. E means an unfavourable proposition for the stated use; C uncertain or limited evidence; B supportive evidence with meaningful limits. There is no blanket grade for HRT, and evidence for symptom relief cannot provide a cancer-safety clearance.
What did the WHI trials actually show about breast cancer?
The combined oral regimen and the estrogen-alone regimen had different findings in different populations.
The original combined trial enrolled postmenopausal women aged 50–79 who had a uterus. It compared oral conjugated equine estrogens plus medroxyprogesterone acetate with placebo. The estrogen-alone trial separately enrolled women with a prior hysterectomy.
In the 2020 follow-up, the combined-regimen group had more breast cancer cases than its placebo group. Its difference in breast cancer deaths was not statistically significant. The estrogen-alone group had fewer cases and deaths than its own placebo group.
The follow-up included years after trial treatment ended. These were not women in one common group randomly assigned to take or omit a progestogen. The results must stay attached to each trial's treatment and participants.
How large was the breast cancer difference in the original combined trial?
The book reports 8 more invasive breast cancer events per 10,000 person-years versus placebo for the original WHI combined regimen.
That difference comes from the 2002 report, across its trial population, during an average 5.2 years of follow-up. It describes oral conjugated equine estrogens plus medroxyprogesterone acetate compared with placebo. It is not a personal forecast or lifetime risk.
Person-years combines the number of people observed and the length of observation. It is a rate denominator, not a statement that every participant took treatment for exactly one year. Do not mix this rate with a cumulative percentage from another study or period.
Ask for both relative and absolute risk, using the same outcome, time period and denominator. A relative increase tells you how rates compare; the absolute difference gives the change a scale.
Does the estrogen-alone result mean I can leave out progesterone?
No. A result in women with a prior hysterectomy does not justify unprotected systemic estrogen when a uterus is present.
Systemic estrogen usually needs an appropriate uterine-lining protection plan in someone with a uterus. The protective component and estrogen exposure must be considered together.
The breast cancer findings for medroxyprogesterone acetate cannot be assigned unchanged to every other progestogen. Equally, choosing another preparation does not resolve every uncertainty about its risks.
If the protective component causes problems, ask the prescriber to review the whole plan. Do not use the estrogen-alone WHI finding as a reason to omit it yourself.
Are patches, gels or ‘bioidentical’ hormones free of breast cancer concerns?
A different route or label does not provide a blanket cancer-safety assurance.
The WHI oral-regimen findings cannot establish identical risks for every patch, gel, spray or hormone combination. Ask what direct evidence supports the exact regimen proposed and which findings come from observational research.
Changing delivery does not cancel every reason a treatment may be unsuitable. Ask the clinician to explain the evidence and remaining uncertainty for the actual preparation.
After breast cancer, a compounded or ‘bioidentical’ preparation cannot be assumed to remove the concern. The HABITS result does not establish the safety of a substitute form.
Can systemic HRT be used after breast cancer?
The book appraises routine systemic hormone use unfavourably in the HABITS trial context; exceptional decisions require specialist assessment.
HABITS found more new breast-cancer events after assignment to systemic hormone therapy, mainly estradiol with a progestogen. Menopause Decoded gives that routine-use proposition E.
A symptom benefit alone cannot settle the cancer-event risk. The actual cancer type, stage, hormone sensitivity, current treatment, recurrence risk and time since treatment all matter.
Involve the oncology team and a suitable menopause specialist when needed. Do not interrupt cancer treatment to manage symptoms without the team's advice. If an option is unsuitable, ask what can be offered instead and who will follow up.
Is low-dose vaginal estrogen safe after breast cancer?
The cancer-safety question remains unresolved, with observational reassurance and an important aromatase-inhibitor subgroup concern.
The Danish cohort found no overall recurrence increase among vaginal-estrogen users, but a higher recurrence signal in the subgroup taking aromatase inhibitors. It was observational, so it cannot prove safety or erase that concern. The book grades the cancer-safety claim C.
Low-dose local treatment has lower systemic exposure than systemic HRT, but ‘local’ does not mean zero absorption. A pooled observational result cannot assign identical safety to every cream, tablet or ring.
For persistent local symptoms despite nonhormonal care, selected patients may discuss treatment with the relevant clinicians. Aromatase-inhibitor users need particular cancer-team input. Record the exact product, reason for use, uncertainty and review plan.
What help remains if hormone treatment is unsuitable?
A restriction on one treatment should still lead to active symptom care and follow-up.
Hot flashes, sleep disruption, pain and vaginal symptoms may need different approaches. Some nonhormonal medicines and products also have interactions or contraindications, so their safety needs its own review.
The book gives MENOS 1 group CBT B for reducing hot-flash and night-sweat problem ratings after breast cancer. That means less symptom burden, not that the symptoms were imaginary or every episode stopped.
Ask for an option suited to the symptom and your cancer treatment, the expected benefit and a named person responsible for follow-up. Bring the full medicine and supplement list; a ‘natural’ label cannot answer an oncology safety question.
Related questions
What to ask at your appointment
- Which exact estrogen, progestogen, route and combination are we discussing, and for which symptom?
- Which study most closely matches that treatment and my circumstances?
- What are the expected benefits and breast cancer risks in absolute terms over the same period?
- How do my personal and family history affect the decision or need for specialist input?
- Which findings come from randomised trials, and which are observational?
- If I have a uterus, how will its lining be protected?
- If I have had breast cancer, does my cancer team need to review this option, particularly with an aromatase inhibitor?
- Which nonhormonal options are suitable with my current medicines and cancer treatment?
- Who will monitor symptoms and safety, and when will we review whether the plan is helping?
Frequently asked questions
Does HRT increase breast cancer risk?
Some regimens do. WHI oral conjugated equine estrogens plus medroxyprogesterone acetate led to more breast cancer cases than placebo. The separate estrogen-alone trial in women with a prior hysterectomy had different findings. One estimate cannot describe every formulation, route or person.
How much did the original WHI combined regimen increase breast cancer events?
The book reports 8 more invasive breast cancer events per 10,000 person-years versus placebo during an average 5.2 years of follow-up in the original trial population. This is a rate for the named oral regimen, not a personal forecast or lifetime risk.
Does estrogen alone have the same breast cancer findings as combined HRT?
No. The WHI estrogen-alone trial in women with a prior hysterectomy had fewer breast cancer cases and deaths than its placebo group in long-term follow-up. The combined trial had more cases. The trials involved different groups and were not a randomised comparison of adding versus omitting a progestogen in one population.
Can I leave out progesterone to reduce breast cancer concerns?
Do not use the estrogen-alone result to omit uterine protection yourself. Systemic estrogen usually needs an appropriate protective plan when a uterus is present. Ask the prescriber to review the entire regimen and your concerns.
Are estrogen patches or bioidentical hormones free of breast cancer risk?
A route or label cannot establish that. WHI oral-regimen findings do not supply identical estimates for every formulation, and a different preparation does not remove uncertainty. After breast cancer, a compounded or bioidentical label cannot establish a safe substitute for the systemic regimens studied.
Can I use systemic HRT after breast cancer?
The book gives the HABITS routine systemic-hormone proposition E because follow-up found more new breast-cancer events. Exceptional decisions need specialist assessment of the actual cancer, symptoms and alternatives, with the relevant cancer team involved.
Is vaginal estrogen safe after breast cancer?
The book grades the cancer-safety claim C. A Danish observational cohort found no overall recurrence increase among vaginal-estrogen users, but a higher recurrence signal in the aromatase-inhibitor subgroup. Exact product and cancer-treatment context matter; local treatment is not zero exposure and needs shared clinical discussion.
Sources
Adapted from Menopause Decoded, First Edition (2026), chapters 21 and 42. The WHI risk figures and the three treatment-specific letter grades follow the final ISBN'd book. No new grade is assigned to its WHI breast-cancer findings. Its targeted source checks extend through 18 September 2026; this guide's review date records the adaptation, not a new systematic review. International sources do not replace current Australian product information or individual oncology and menopause care.
- WHI — original combined oral hormone trial (2002)
- WHI — long-term breast cancer incidence and mortality follow-up (2020)
- The Menopause Society — 2022 Hormone Therapy Position Statement
- HABITS — new breast-cancer events after systemic hormone therapy
- Danish observational cohort — systemic or vaginal hormones after early breast cancer
- ACOG — urogenital symptom care after estrogen-dependent breast cancer
- MENOS 1 — group CBT for menopausal symptom burden after breast cancer
- NICE — menopause identification and management
This guide provides general education and cannot calculate your personal breast cancer risk or decide whether hormone therapy is suitable. Discuss starting, changing or continuing treatment with a qualified clinician who knows your history; cancer-related decisions may need your oncology team and a menopause specialist. Read the full Medical Disclaimer.